



Synthesis of New Organotin(IV) *N*-methyl-*N*-benzyl Dithiocarbamate Compounds and Cytotoxicity assessment on Human Lung Carcinoma Cell Line (A549)

NURUL AMALINA ABD AZIZ¹, NUR ATIYAH NADHRAH JAMALUDIN¹,
NORMAH AWANG^{2*}, NURUL FARAHANA KAMALUDIN², KOK MENG CHAN²
and NUR NAJMI MOHAMAD ANUAR²

¹Environmental Health and Industrial Safety Program, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia.

²Center for Toxicology and Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia.

*Corresponding author E-mail: norm@ukm.edu.my

<http://dx.doi.org/10.13005/ojc/390403>

(Received: April 07, 2023; Accepted: July 14, 2023)

ABSTRACT

Using the *in situ* method, the successful synthesis of dibutyltin(IV) *N*-methyl-*N*-benzyl dithiocarbamate (Compound 1) and tricyclohexyltin(IV) *N*-methyl-*N*-benzyl dithiocarbamate (Compound 2) was achieved. Both compounds were characterized by the CHNS elemental analysis, FTIR, NMR spectroscopies and X-ray crystallography study. The experimental CHNS values demonstrated good congruence with the CHNS's theoretical values of the suggested formula structures. The key infrared absorbance peaks, $\nu(\text{C-N})$ and $\nu(\text{C-S})$, which were found between 1475–1481 cm^{-1} and 971–975 cm^{-1} , respectively. The ^{13}C chemical shift of carbon in the NCS_2 group was observed in the range of 200.66–202.32 ppm. The crystal structure of Compound 1 shows the anisobidentate's coordination mode between the central metal of the Sn atom and the dithiocarbamate ligands. Compound 1 and Compound 2 have shown great toxicity effects against carcinoma cells in the human lung (A549) with lower IC_{50} values of 0.80 μM and 2.77 μM , respectively.

Keywords: Organotin, Dithiocarbamate, A549 cells, Cytotoxicity, Anticancer.

INTRODUCTION

In developing and developed nations, a major cause of death is cancer. Cancer was responsible for nearly 10 million deaths in 2020. Worldwide, in statistical terms, most of these occurred due to lung cancer, after which came colorectal cancer, cancers of

the liver and stomach, and breast cancer in females¹. Meanwhile, in Malaysia, patients with lung cancer have a low survival rate in comparison to those with different forms of cancer since nearly one in ten generally obtain a diagnosis when their situation is critical, at stages III or IV². This leads to an urgent study to discover useful anticancer drugs for lung cancer patients.



Chemotherapy, surgery, radiotherapy, and targeted therapy are commonly used for lung cancer treatment³. Nevertheless, when treating patients with lung cancer, particularly if they have NSCLC, the typical form of care remains platinum-based chemotherapy⁴, with the standard drug utilized generally being cisplatin^{5,6}. The action of cisplatin is to bind to the N7 reactive center on purine residues, resulting in damage to the deoxyribonucleic acid of the cancer cells and apoptotic cell death⁷. Although cisplatin is an effective anticancer agent, its side effects and resistance limit its clinical use in cancer treatment⁸. Certain patients can experience side effects such as nephrotoxicity, nausea, hepatotoxicity, cardiotoxicity and neurotoxicity from cisplatin. Meanwhile, damage to DNA can be repaired to a greater extent and the cisplatin's accumulation intracellular and cytosolic inactivation can be reduced, which are the principal causes of the development of resistance to cisplatin⁹.

As a result, scientists have conducted several studies to replace existing treatments, including using non-platinum metals, such as organotin(IV). The anti-tumor properties of the first organotin(IV) compounds have been studied, and they have shown properties almost identical to cisplatin¹⁰. Recent studies have highlighted the therapeutic potential of the organotin(IV) dithiocarbamate compounds¹¹⁻¹³. At even a low concentration, an organotin(IV) compound has high toxicity and, in cancer cells, they display anticancer activity through gene-mediated pathways¹⁴. The coordination number as well as the characteristics of groups bonded to the centre of tin atom are responsible for the ability to bind to this type of compound's DNA¹⁴. The complexes formed from the binding of organotin(IV) compounds with stable ligands like dithiocarbamate might cause them to have greater lipophilic properties, thus creating reactions with the components of the cells, which might result in the cells dying¹⁵⁻¹⁷. Therefore, the synthesizing, characterizing, and evaluating the cytotoxic effects of novel organotin(IV) dithiocarbamate compounds against carcinoma cells in the human lung (A549) will be conducted in the study.

MATERIALS AND METHODS

Reagents

The following suppliers sold all the chemicals and reagents involved, which were

utilized precisely as received: *N*-methylbenzylamine, dibutyltin(IV) dichloride, tricyclohexyltin(IV) chloride, and cisplatin (Sigma-Aldrich, Germany); ethanol and chloroform (System, Malaysia); carbon disulfide and ammonia solution 25% were supplied by Merck; DMSO (Sigma-Aldrich, USA).

Synthesis of organotin(IV) *N*-methyl-*N*-benzyl dithiocarbamate

Two compounds were synthesized via the *in situ* method by the reaction between organotin(IV) salt and secondary amines. According to the molar ratio of 1:1 and 2:1 for triorganotin(IV) and diorganotin(IV), respectively, dibutyltin(IV) dichloride and tricyclohexyltin(IV) chloride was allowed to react with the secondary amines; *N*-methylbenzylamine and carbon disulfide in ethanolic solution. For 120 min at a temperature under 4°C, stirring of the reaction mixture was performed. After filtering, cold ethanol was used to wash the mixture. Upon the formation of white precipitate, it was left to dry in a desiccator over several days.

Physical Measurement

Both of synthesized compounds were characterized by using analytical techniques and basic spectroscopies, including CHNS elemental analysis, FTIR spectroscopy, NMR spectroscopy, and an X-ray single crystallography study. MPA120 EZ-Melt automated melting point apparatus was used to measure the melting points of each compound. The melting point of a pure compound should be in the range of 1–3°C. Next, the CHNS Elemental Analyzer model Perkin Elmer 2400 was used to elementally analyze the carbon, hydrogen, nitrogen, and sulfur, whereby a comparison was made between the analytical value and theoretical percentage. Next, the infrared spectra of each compound were determined by using a Bruker (Vertex 70v) FTIR Spectrometer in the spectral range of 4000–80 cm⁻¹. Functional groups presence in each compound could be detected through FT-IR analysis. The chemical shifts of ¹H, ¹³C, and ¹¹⁹Sn NMR spectra were obtained by using an NMR spectrophotometer model Bruker AVANCE 400 III HD in CdCl₂, with tetramethylsilane as an internal standard.

A Rigaku single-crystal X-ray diffractometer was used to determine compound's crystal structure. Both FTIR and X-ray single crystallography study was

conducted at Sunway University. The measurements of CHNS analysis were conducted at the Organic Synthesis Research Laboratory, Institute of Science, Universiti Teknologi MARA (UiTM) Puncak Alam, whereby the NMR spectroscopies were conducted in Centre for Research and Instrumentation Management (CRIM), UKM.

Recrystallization and Crystallographic study

To perform the stages of crystallization, the compound was dissolved at room temperature in a solution of ethanol and chloroform at a 1:2 v/v ratio. Then, the mixture was slowly evaporated for three to four days until colorless crystals formed. The formed crystals were harvested and then examined using X-ray crystallography in a cold liquid nitrogen stream.

Cell and Cell Culture

Human lung carcinoma cells (A549) were purchased from the American Type Culture Collection (ATCC). A549 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Sigma USA). The L-glutamine-enriched media were supplemented with 1% penicillin/streptomycin and 10% fetal bovine serum (FBS).

MTT Cytotoxicity Assay

By using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay¹⁸, the synthesized compounds were screened against the A549 cell line. Six concentrations of the serial dilution of each compound were formulated, including 0.16 μM , 0.31 μM , 0.63 μM , 1.25 μM and 2.5 μM , with the highest being 5.00 μM . In the MTT assay, the positive control utilized was cisplatin; meanwhile, a negative control was provided by the untreated cells. The A549 cells were seeded in a 96-well plate at a density of $5 \times 10^4 \text{ mL}^{-1}$ and incubated overnight at 37°C in 5% CO_2 . Following incubation for 24 h the removal of the media from each well occurred, with each compound used to replace them. After the cells had been treated for 24 h, 20 μL of MTT was added to each well in a dark environment because MTT is light-sensitive. Following this, a four-hour incubation of the cells took place, after which the removal from each well of 180 μL of supernatant occurred. Then, the newly formed formazan crystals were dissolved with the addition of 180 μL DMSO. Once DMSO had been introduced, a 15 min incubation of the 96-well plate was performed again. At 570 nm, a Multiskan GO microplate reader (Thermo Fisher Scientific) was used to detect the compounds' cytotoxicity effects. To plot the cytotoxicity graphs, the viable-cell

percentages and compound concentrations were set against each other. Once the graphs had been plotted, the IC_{50} values could be ascertained, indicating that in comparison to the cells that had not been treated, the cell population in the treated cells had been halved.

Statistical analysis

The data obtained from this study was analyzed using one-way ANOVA by using IBM Statistical Package for Social Sciences (SPSS). The data is statistically significant when $p < 0.05$.

RESULTS AND DISCUSSION

Synthesis of Compounds 1 and 2

Two new organotin(IV) dithiocarbamate compounds were synthesized by using the *in situ* method in this study. Both compounds were synthesized through the reactions of organotin(IV) salt [dibutyltin(IV) dichloride or tricyclohexyltin(IV) chloride] and secondary amines [*N*-methylbenzylamine] in the presence of carbon disulphide in ethanol. The compounds were synthesized in an ice bath at temperatures below 4°C to prevent the dithiocarbamate ligand from decomposing. Two hours later, after filtration, cold ethanol was used to wash the mixture three times. The mixture was left to dry in a desiccator up to the point at which a white powder of the compounds had been produced.

Table 1 shows the compounds' physical characteristics and the data related to the analysis. Based on Table 1, the percentage yields of both compounds were in the range of 57.6–75.3%, which is higher than 50% of the theoretical yield. Both compounds can be assumed to be pure compounds because their melting points were less than 3°C. Found to be white solids, at room temperature, each compound (1 and 2) was stable in the atmosphere. Using the recommended formula, the values from the experiment and the theory demonstrated good agreement with the data from the C, H, N, and S elemental analysis.

The results of two newly synthesized organotin(IV) *N*-methyl-*N*-benzylidithiocarbamate compounds are confirmed to be similar to the suggested structural formula. The structural formulas for these compounds are dibutyltin(IV) *N*-methyl-*N*-benzylidithiocarbamate ($\text{C}_4\text{H}_9\text{Sn}[\text{S}_2\text{CN}(\text{CH}_3(\text{C}_6\text{H}_5)(\text{CH}_2)_2]$ (Compound 1) (Fig. 1) and tricyclohexyltin(IV) *N*-methyl-*N*-benzylidithiocarbamate ($\text{C}_6\text{H}_{11}\text{Sn}[\text{S}_2\text{CN}(\text{CH}_3(\text{C}_6\text{H}_5)(\text{CH}_2)_2]$ (Compound 2) (Figure 2).




Fig. 1. The chemical structure of Compound 1




Fig. 2. The chemical structure of Compound 2

Table 1: The Physical Properties and Elemental Analytical Data of Compounds 1 and 2

Molecular formula	Color	Yield(%)	Melting Point (°C)	C	H	N	S
Compound 1 (C ₄ H ₉) ₂ Sn[S ₂ CN(CH ₃ (C ₆ H ₅)(CH ₂) ₂)]	White	75.3	92.4–94.4	48.66	5.98	4.31	20.08
Compound 2 (C ₆ H ₁₁) ₂ Sn[S ₂ CN(CH ₃ (C ₆ H ₅)(CH ₂) ₂)]	White	57.6	72.6–74.6	57.35 57.45	8.12 7.68	1.55 2.48	8.79 11.36

*Bold: Theoretical value

Infrared Spectroscopy Analysis

The key vibrational bands obtained using Fourier-transform infrared (FTIR) spectroscopy for compounds 1 and 2 are shown in Table 2. The important absorbance peaks that identify the presence of dithiocarbamate ligands were based on the presence of $\nu(\text{C}=\text{N})$ and $\nu(\text{C}=\text{S})$. The $\nu(\text{C}=\text{N})$ band, also known as the thiouride band, was discovered in the 1475–1481 cm^{-1} range. The thiouride band is usually observed in the range of wavelengths between 1450 and 1550 cm^{-1} ^{19,20}. Adeyemi *et al.*, (2019) reported the existence of the thiouride band at wavelengths ranging from 1443 to 1488 cm^{-1} ²¹.

Meanwhile, the $\nu(\text{C}=\text{S})$ band was discovered at 971–975 cm^{-1} . The presence of the $\nu(\text{C}=\text{S})$ absorption band in the infrared spectrum indicates the mode of coordination of the ligand with the central metal, either monodentate or bidentate²². The bonding between the Sn atom and the organotin(IV) compound can be determined by the presence of (Sn-C). The (Sn-C) band was found in the spectral range of 496–552 cm^{-1} ^{11,23}. Therefore, as revealed in the analysis, dithiocarbamate groups and organotin(IV) compounds were present, which were comprised of the recommended formulae for each compound and fulfilled the criteria proposals of prior researchers.

Table 2: Infrared Absorption Bands of Compounds 1 and 2

Compound	Wavelength (cm ⁻¹)					
	$\nu(\text{C-H})$	$\nu(\text{C}=\text{N})$	$\nu(\text{N-C})$	$\nu(\text{C}=\text{S})$	$\nu(\text{Sn-C})$	$\nu(\text{Sn-S})$
1	3057	1481	1239	975	552	382
2	2915	1475	1246	971	496	379

Nucleus Magnetic Resonance Spectroscopy Analysis

Apart from FTIR analysis, NMR analysis has also been carried out to identify the molecular structure, ¹H, ¹³C, and ¹¹⁹Sn atoms in each of the synthesized compounds. Based on Table 3, the ¹H proton NMR of Compounds 1 and 2 shows the presence of a single signal for the methyl proton directly

bound to the N atoms in dithiocarbamate at 3.328 ppm and 3.388 ppm²⁴, respectively. Besides, the methylene proton of methylene group attached directly to the N atom of dithiocarbamate ligands were observed in the range of 5.148–5.255 ppm²⁵. A broad signal for the butyl group attached to the Sn atom was found in the range of 0.972–2.127 ppm^{11,26}, confirming that it's attached to the Sn atom, which is electropositive, through the

nuclei of carbon. This causes shielding, which occurs through the carbon chain²⁷.

Meanwhile, in Compound 2, proton signals in a range of 1.374–2.047 ppm were assigned for the tricyclohexyl group on the tin(IV) atom²⁸. The aromatic multiplet signal of the proton of the phenyl group bound to Compounds 1 and 2 was observed in the chemical shift

range of 7.249–7.374 ppm and 7.270–7.385 ppm, respectively. Consistently, the chemical shifts of 7.27 to 8.07 ppm were reported for the proton of the phenyl group (C₆H₅-N)^{17,29}. Furthermore, for bis(*p*-substituted-*N*-methyl benzyl dithiocarbamate) compound that was synthesized by Khan *et al.*, (2015), the chemical shift of the aromatic proton of the phenyl group were observed in a range of 7.14–7.94 ppm²⁷.

Table 3: ¹H NMR Spectra Data of Compound 1 and Compound 2

Compound	Chemical shifts, δ (ppm)			
	N-R'(R''=CH ₃)	-NR'(R'=CH ₂)	-NR'R aromatic	Sn-R(R=C ₄ H ₉ , C ₆ H ₁₁)
1	3.328	5.148	7.249–7.374	CH ₂ : 2.127 CH ₂ : 1.986 CH ₂ : 1.512 CH ₃ : 0.972
2	3.388	5.255	7.270–7.385	1.374–2.047

Next, the presence of each carbon signal in the synthesized compound can be identified through the ¹³C NMR spectra. Table 4 shows the data spectra of ¹³C NMR. An important chemical shift in characterizing organotin(IV) dithiocarbamate compounds is the CS₂ carbon signal. The carbon atom signal in N-CS₂ of Compounds 1 and 2, appears in the chemical shift range between 200.66 and 202.32 ppm. The signal is usually observed in the chemical shift range of 185–220 ppm³⁰. Through the CS₂ signal, it shows that the sulfur atom has formed a bond with the central metal of the Sn atom in the compound¹³.

Furthermore, carbon signals for other carbon-containing substances were also observed in the ¹³C NMR spectroscopy. Signals derived from the methylene carbon near the electronegative atom of nitrogen appeared to range from 59.95 to 60.70 ppm^{11,31}. The resonance between 13.89 ppm and 34.46 ppm was observed for the dibutyltin(IV) compound³², where the chemical shift in the range of 26.20–34.76 ppm was assigned for the

tricyclohexyltin(IV) compound²⁸. The diphenyl complex was obtained within the 127.45 to 135.83 ppm region, which corresponded to the information provided by Haezam *et al.*,¹³ that showed resonance in the range of 119.0–136.75 ppm.

Table 5 shows the data spectra of the ¹¹⁹Sn NMR of Compounds 1 and 2. The coordination number of the synthesized compound's Sn atom was determined through analysis using ¹¹⁹Sn NMR spectroscopy. The result shows the ¹¹⁹Sn spectra for Compounds 1 and 2 are in the range of –338.75 to –22.55 ppm. It explains that Compounds 1 and 2 have the expected coordination geometry of hepta³³ and tetra³⁴ around the tin center, respectively. The signal of the complex can have the same coordination and various chemical shifts in ¹¹⁹Sn due to its dependence on the R group's number and characteristics, as well as the characteristics of the dithiocarbamate ligand to which the Sn atom is bound³⁵. This may be due to the sensitivity of the chemical environment of tin^{36,37}.

Table 4: ¹³C NMR Spectra Data of Compounds 1 and 2

Compound	Chemical shifts, δ (ppm)				
	N-CS ₂	Sn-R(R=C ₄ H ₉ , C ₆ H ₁₁)	N-CH ₂ C ₆ H ₅	N-CH ₃	N-CH ₂ C ₆ H ₅
1	202.32	13.89(CH ₂), 26.48(CH ₂), 28.70(CH ₂), 34.46 (CH ₃)	59.95	41.77	127.55, 127.92, 128.83, 135.36
2	200.66	26.20–34.76	60.70	42.52	127.45, 127.71, 128.74, 135.83

Table 5: ¹¹⁹Sn NMR Spectra Data of Compounds 1 and 2

Compound	Chemical shifts ¹¹⁹ Sn, δ (ppm)
1	–338.75
2	–22.55

X-ray single crystallography study

The data related to crystallography and refinement are shown in Table 6, while compound 1's chosen bond lengths and angles are shown in Table 7. The recrystallization process was

carried out for both synthesized compounds through an evaporation process at room temperature using a mixture of two solvents: ethanol and chloroform at a certain ratio (1:2 v/v). Once evaporation at room temperature over a number of days had taken place, colorless crystals had been formed by only compound 1. Compound 1 (dibutyltin(IV) *N*-methyl-*N*-benzylidithiocarbamate) has a colorless crystal structure with dimensions of 0.27x0.20x0.11 mm and a molecular mass of 625.57 g. Compound 1's single crystal is in the triclinic system and the P1 space, where $\alpha = 9.6272(1) \text{ \AA}$, $b = 12.1043(2) \text{ \AA}$, $c = 13.3584(2) \text{ \AA}$, $\alpha = 82.296(1)^\circ$, $\beta = 86.611(1)^\circ$.

A significant difference can be detected in the bond distance of the four sulfur atoms that coordinate with the Sn atom, which is Sn-S1 = 2.5334(4) and Sn-S3 = 2.5497(4). The central metal, Sn (IV) is covalently bonded to S1 and S3 within a normal Sn-S bond distance of 2.48–2.57 \AA ²³. The asymmetric coordination of the dithiocarbamate ligands results in a large disparity of C-S bond lengths, with C1-S1 bonds being shorter than S2-bonds [C1-S1, S2 = 1.7477(19) & 1.6910(19) \AA and 1.7528(19) & 1.6944(19) \AA]. The crystal structure of Compound 1 shows the coordination mode by anisobidentate between the central metal of the Sn atom and the dithiocarbamate ligands. The C19-Sn-C23 for this compound is 137.83(7)° which is larger than the ideal angle for a tetrahedron (109.5°)^{17,34}, resulting in a distorted tetrahedron geometry. However, the S1-Sn-S3 bond angle which falls at 80.289(14)° was parallel to the $S_{\text{short}}\text{-Sn-}S_{\text{short}}$ bond angles reported in previous studies (78°–88°)²³.

Figure 3 portrays the plotted ORTEP of Compound 1. The coordinate geometry depicted in the X-ray single crystal crystallographic analysis results is described as a skewed trapezoidal-bipyramidal geometry with a short trapezoidal edge formed through strong bonds between S1 and S3, while S2 and S4 bonds affect the length of the sides of the geometry.

Table 6: Crystallographic Data and Refinement Parameters for Compound 1³⁸

Chemical formula	C ₂₆ H ₃₈ N ₂ S ₄ Sn
Molar mass (g)	625.57
α (\AA)	9.6272(1)
b (\AA)	12.1043(2)
c (\AA)	13.3584(2)
α ($^\circ$)	82.296(1)
β ($^\circ$)	86.611(1)
γ ($^\circ$)	66.912(1)
V (\AA^3)	1419.02(4)
Z	2
R_{gt} (F)	0.0235
wR_{ref} (F ²)	0.0612
SuhuT(K)	100
μ (mm ⁻¹)	10.0
Wavelength	Cu K α radiation (1.54184 \AA)
Diffraction, scan mode	XtaLAB Synergy, ω
θ_{max} , completeness	75.3°, >99%
$N(\text{hkl})_{\text{measured}}$	
$N(\text{hkl})_{\text{unique}}$, R_{int}	37, 119, 5854, 0.033
Criterion for I_{obs} , $N(\text{hkl})_{\text{gt}}$	$I_{\text{obs}} > 2\sigma(I_{\text{obs}})$, 5841
$N(\text{param})_{\text{refined}}$	302
Programs	CrysAlis ^{PRO} , SHELX, W_{IN} GX/ORTEP

Table 7: Selected bond length (\AA) and angles ($^\circ$) for Compound 1

Bond lengths (\AA)		Bond angles ($^\circ$)	
Sn-C19	2.1479(18)	C19-Sn-C23	137.83(7)
Sn-C23	2.1530(18)	C19-Sn-S1	109.80(5)
Sn-S1	2.5334(4)	C23-Sn-S1	103.99(5)
Sn-S3	2.5497(4)	C19-Sn-S3	104.60(5)
S1-C1	1.7477(19)	C23-Sn-S3	105.32(5)
S2-C1	1.6910(19)	S1-Sn-S3	80.29(14)
S3-C10	1.7528(19)	C1-S1-Sn	94.16(6)
S4-C10	1.6944(19)	C10-S3-Sn	95.34(6)
N1-C1	1.337(2)	C1-N1-C2	122.40(16)
N1-C2	1.463(2)	C1-N1-C9	119.73(16)
N1-C9	1.465(2)	C2-N1-C9	117.72(15)
N2-C10	1.335(2)	C10-N2-C18	120.59(16)
N2-C18	1.467(2)	C10-N2-C11	124.05(15)
N2-C11	1.475(2)	C18-N2-C11	115.35(15)
C2-C3	1.519(3)	N1-C1-S2	122.35(14)
C3-C8	1.391(3)	N1-C1-S1	118.35(14)
C3-C4	1.391(3)	S2-C1-S1	119.30(11)
C4-C5	1.388(3)	N1-C2-C3	114.04(15)
C5-C6	1.391(3)	N2-C10-S4	122.09(14)
C6-C7	1.384(3)	N2-C10-S3	118.89(14)
C7-C8	1.392(3)	S4-C10-S3	119.01(10)
C11-C12	1.514(3)	N2-C11-C12	112.93(15)
C12-C13	1.388(3)	C20-C19-Sn	112.43(13)




Fig. 3. ORTEP plot of Compound 1

Cytotoxicity of organotin(IV) *N*-methyl-*N*-benzyl dithiocarbamate compounds in A549 cells

Table 8 shows the IC_{50} values for Compound 1 (dibutyltin(IV) *N*-methyl-*N*-benzyl dithiocarbamate) and Compound 2 (tricyclohexyltin(IV) *N*-methyl-*N*-benzyl dithiocarbamate). As shown by the MTT assay findings, each compound had a major cytotoxic effect on carcinoma cell lines in the human lung (A549). However, based on the inhibitory IC_{50} values of Compounds 1 and 2 at $0.80 \mu\text{M}$ (0.50 g/cm^3) and $2.77 \mu\text{M}$ (1.56 g/cm^3), it is observed that Compound 1 is highly toxic. Moreover, when compared with a standard drug, cisplatin, both compounds exhibit higher cytotoxicity activity toward A549 cell lines. As shown in Fig. 4, after being treated for 24 h the cytotoxic effects against A549 cells of organotin(IV) *N*-methyl-*N*-benzyl dithiocarbamate compounds could be identified.

Compound 1, which is dibutyltin(IV) *N*-methyl-*N*-benzyl dithiocarbamate, has a stronger cytotoxic effect than tricyclohexyltin(IV) *N*-methyl-*N*-benzyl dithiocarbamate because the toxicity is dependent on the structure of the compound. Study by Pellerito *et al.*, (2006) stated that certain elements or functional groups in a compound provide different proliferative effects to treated cells³⁹. Furthermore, the cytotoxic effect can be influenced by the length and count of the alkyl groups connected to the metal tin atom in the center⁴⁰. Greater toxicity is evident in organotin compounds that are highly substituted; meanwhile, compounds' cytotoxic effects are enhanced by shorter alkyl substituents⁴¹⁻⁴³. Thus, the conclusion was that these published data demonstrated the generally greater anticancer activity of the diorganotin compound, compared to the triorganotin (IV) compound.

Table 8: IC_{50} values of Compound 1 and Compound 2 against A549 cells

Compound	$IC_{50}(\mu\text{M}) \pm \text{S.E.M}$
1	0.80 ± 0.09
2	2.77 ± 0.34
Cisplatin	32.00 ± 0.29




Fig. 4. The cytotoxicity of organotin(IV) *N*-methyl-*N*-benzyl dithiocarbamate compounds against A549 cells upon a 24-h treatment. The data show cell viability (%) \pm S.E.M obtained from three separate experiments

CONCLUSION

Utilizing the *in situ* method enabled the successful synthesis of two novel organotin(IV) obtained via *N*-methyl-*N*-benzyl dithiocarbamate. Elemental and spectroscopies analysis, namely CHNS analysis, FT-IR and NMR spectroscopies were then employed to characterize these compounds. In general, the theoretical CHNS values were exhibited by the experimental CHNS values of each compound. Moreover, each compound displayed the presence of crucial absorbance peaks: $\nu(\text{C}=\text{N})$, $\nu(\text{C}=\text{S})$, $\nu(\text{Sn}-\text{S})$ and $\nu(\text{Sn}-\text{C})$ which indicates that the organotin(IV) dithiocarbamate compounds have formed. Furthermore, the presence of significant nuclear magnetic resonance (NMR) signals confirms the structure of compounds obtained. An X-ray single crystallography study was also used to determine the crystal structure of dibutyltin(IV) *N*-methyl-*N*-benzyl dithiocarbamate (Compound 1). The result showed that the geometry of Compound 1 is a skewed trapezoidal bipyramidal with a short trapezoidal edge. Both compounds showed strong toxicity against A549 cells compared to cisplatin, with Compound 1 being more potent than Compound 2.

ACKNOWLEDGEMENT

We would like to thank the Ministry of

Higher Education (FRGS/1/2021/STG04/UKM/02/5) for the financial support given to this study. We would also like to acknowledge the Faculty of Health Sciences of Universiti Kebangsaan Malaysia and Sunway University for the technical support provided in this study. Additionally, we would like to thank the Center for Research and Instrumentation

Management (CRIM), UKM and Organic Synthesis Research Laboratory, Institute of Science (UiTM) for the laboratory services given.

Conflicts of interest

The authors declare that they have no conflict of interest.

REFERENCES

- Sung, H.; Ferlay, J.; Siegel, R. L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.*, **2021**, *71*(3), 209–249.
- Rajadurai, P.; How, S. H.; Liam, C. K.; Sachithanandan, A.; Soon, S. Y.; Tho, L. M. Lung Cancer in Malaysia. *Journal of Thoracic Oncology*, **2020**, *15*(3), 317-323.
- Lemjabbar-Alaoui, H.; Hassan, O. U. I.; Yang, Y. W.; Buchanan, P. Lung Cancer: Biology and Treatment Options. *Biochim. Biophys. Acta Rev. Cancer*, **2015**, *1856*(2), 189–210.
- Rossi, A.; Di Maio, M. Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Optimal Number of Treatment Cycles. *Expert Rev. Anticancer Ther.*, **2016**, *16*(6), 653–660.
- Bunn, P. A. The Expanding Role of Cisplatin in the Treatment of Non-Small-Cell Lung Cancer. *Semin. Oncol.*, **1989**, *16*(4 Suppl 6), 10–21.
- Chen, Y. J.; Wang, Z. W.; Lu, T. L.; Gomez, C. B.; Fang, H. W.; Wei, Y.; Tseng, C. L. The Synergistic Anticancer Effect of Dual Drug-(Cisplatin/Epigallocatechin Gallate) Loaded Gelatin Nanoparticles for Lung Cancer Treatment. *J. Nanomater.*, **2020**, *2020*, 1-15.
- Dasari, S.; Bernard Tchounwou, P. Cisplatin in Cancer Therapy: Molecular Mechanisms of Action. *Eur. J. Pharmacol.*, **2014**, *740*, 364–378.
- Brown, A.; Kumar, S.; Tchounwou, P. B. Cisplatin-Based Chemotherapy of Human Cancers. *J. Cancer Sci. Ther.*, **2019**, *11*(4), 97.
- Aldossary, S. A. Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin. *Biomed. Pharmacol. J.*, **2019**, *12*(1), 7-15.
- Gielen, M. Organotin Compounds and Their Therapeutic Potential: A Report from the Organometallic Chemistry Department of the Free University of Brussels. *Applied Organometallic Chemistry*, **2002**, *16*(9), 481-494.
- Adeyemi, J. O.; Onwudiwe, D. C.; Nundkumar, N.; Singh, M. Diorganotin(IV) Benzylidithiocarbamate Complexes: Synthesis, Characterization, and Thermal and Cytotoxicity Study. *Open Chem.*, **2020**, *18*(1), 453-462.
- Hamid, A.; Azmi, M. A.; Rajab, N. F.; Awang, N.; Jufri, N. F. Cytotoxic Effects of Organotin(IV) Dithiocarbamate Compounds with Different Functional Groups on Leukemic Cell Line, K-562. *Sains Malays.*, **2020**, *49*(6), 1421–1430.
- Haezam, F. N.; Awang, N.; Kamaludin, N. F.; Mohamad, R. Synthesis and Cytotoxic Activity of Organotin(IV) Diallyldithiocarbamate Compounds as Anticancer Agent towards Colon Adenocarcinoma Cells (HT-29). *Saudi J. Biol. Sci.*, **2021**, *28*(5), 3160–3168.
- Tabassum, S.; Pettinari, C. Chemical and Biotechnological Developments in Organotin Cancer Chemotherapy. *J. Organomet. Chem.*, **2006**, *691*, 1761–1766 .
- Cvek, B.; Dvorak, Z. Targeting of Nuclear Factor-KappaB and Proteasome by Dithiocarbamate Complexes with Metals. *Curr. Pharm. Des.*, **2007**, *13*(30), 3155–3167.
- Javed, F.; Sirajuddin, M.; Ali, S.; Khalid, N.; Tahir, M. N.; Shah, N. A.; Rasheed, Z.; Khan, M. R. Organotin(IV) Derivatives of o-Isobutyl Carbonodithioate: Synthesis, Spectroscopic Characterization, X-Ray Structure, HOMO/LUMO and *In vitro* Biological Activities. *Polyhedron*. **2016**, *104*, 80–90.
- Kamaludin, N. F.; Awang, N.; Baba, I.; Hamid, A.; Meng, C. K. Synthesis, Characterization and Crystal Structure of Organotin(IV) N-Butyl-N-Phenyldithiocarbamate Compounds and Their Cytotoxicity in Human Leukemia Cell Lines. *Pak. J. Biol. Sci.*, **2013**, *16*(1), 12–21.
- Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. *J. Immunol. Methods.*, **1983**, *65*(1–2), 55–63.

19. Nomura, R.; Takabe, A.; Matsuda, H. Facile Synthesis of Antimony Dithiocarbamate Complexes. *Polyhedron.*, **1987**, *6*(3), 411-416.
20. Brown, D. A.; Glass, W. K.; Burke, M. A. The General Use of i.r. Spectral Criteria in Discussions of the Bonding and Structure of Metal Dithiocarbamates. *Spectrochim. Acta A.*, **1976**, *32*(1), 137-143.
21. Adeyemi, J. O.; Onwudiwe, D. C.; Singh, M. Synthesis, Characterization, and Cytotoxicity Study of Organotin(IV) Complexes Involving Different Dithiocarbamate Groups. *J. Mol. Struct.*, **2019**, *1179*, 366–375.
22. Yin, H. D.; Xue, S. C. Synthesis and Characterization of Organotin Complexes with Dithiocarbamates and Crystal Structures of (4-NCC₆H₄CH₂)₂Sn(S₂CNET₂)₂ and (2-ClC₆H₄CH₂)₂Sn(Cl)S₂CNBz₂. *Appl. Organomet. Chem.*, **2006**, *20*(4), 283–289.
23. Kamaludin, N. F.; Awang, N. Synthesis and Characterisation of Organotin(IV) Nethyl-N-Phenyldithiocarbamate Compounds and the Crystal Structures of Dibutyl- And Triphenyltin(IV) Nethyl-N-Phenyldithiocarbamate. *Res. J. Chem. Environ.*, **2014**, *18*(11), 99-107.
24. Onwudiwe, D. C.; Ajibade, P. A. Synthesis, Characterization and Thermal Studies of Zn(II), Cd(II) and Hg(II) Complexes of N-Methyl-N-Phenyldithiocarbamate: The Single Crystal Structure of [(C(6)H(5))(CH(3))NCS(2)](4)Hg(2). *Int. J. Mol. Sci.*, **2011**, *12*(3), 1964–1978.
25. Maurya, V. K.; Singh, A. K.; Singh, R. P.; Yadav, S.; Kumar, K.; Prakash, P.; Prasad, L. B. Synthesis and Evaluation of Zn(II) Dithiocarbamate Complexes as Potential Antibacterial, Antibiofilm, and Antitumor Agents. *J. Coord. Chem.*, **2019**, *72*(19–21), 3338-3358.
26. Awang, N.; Baba, I.; Yamin, B. M.; Othman, M. S.; Kamaludin, N. F. Synthesis, Characterization and Biological Activities of Organotin(IV) Methylcyclohexyldithiocarbamate Compounds. *Am. J. Appl. Sci.*, **2011**, *8*(4), 310-317.
27. Khan, N.; Farina, Y.; Mun, L. K.; Rajab, N. F.; Awang, N. Syntheses, Characterization, X-Ray Diffraction Studies and *In vitro* Antitumor Activities of Diorganotin(IV) Derivatives of Bis(p-Substituted-N-Methylbenzylaminedithiocarbamates). *Polyhedron.*, **2015**, *85*, 754-760.
28. Mohamad, R.; Awang, N.; Farahana Kamaludin, N. Synthesis and Characterisation of New Organotin(IV)(2-Methoxyethyl)-Methyldithiocarbamate Complexes. *Res. J. Pharm. Biol. Chem. Sci.*, **2016**, *7*(2), 1920-1925.
29. Ajibade, P. A.; Onwudiwe, D. C.; Moloto, M. J. Synthesis of Hexadecylamine Capped Nanoparticles Using Group 12 Complexes of N-Alkyl-N-Phenyl Dithiocarbamate as Single-Source Precursors. *Polyhedron.*, **2011**, *30*(2), 246-252.
30. Van Gaal, H. L. M.; Diesveld, J. W.; Pijpers, F. W.; Van Der Linden, J. G. M. ChemInform Abstract: Carbon-¹³NMR Spectra of Dithiocarbamates. Chemical Shifts, Carbon-Nitrogen Stretching Vibration Frequencies and II-Bonding in the NCS₂ Fragment. *Inorg. Chem.*, **1979**, *11*(8), 3251–3260.
31. Awang, N.; Kamaludin, N. F.; Baba, I.; Chan, K. M.; Rajab, N. F.; Hamid, A. Synthesis, Characterization and Antitumor Activity of New Organotin(IV) Methoxyethyldithiocarbamate Complexes. *Orient. J. Chem.*, **2016**, *32*(1), 101–107.
32. Sirajuddin, M.; Ali, S.; McKee, V.; Zaib, S.; Iqbal, J. Organotin(IV) Carboxylate Derivatives as a New Addition to Anticancer and Antileishmanial Agents: Design, Physicochemical Characterization and Interaction with Salmon Sperm DNA. *RSC Adv.*, **2014**, *4*(101), 57505–57521.
33. Chans, G. M.; Nieto-Camacho, A.; Ramirez-Apan, T.; Hernandez-Ortega, S.; Alvarez-Toledano, C.; Gomez, E. Synthetic, Spectroscopic, Crystallographic, and Biological Studies of Seven-Coordinated Diorganotin(IV) Complexes Derived from Schiff Bases and Pyridinic Carboxylic Acids. *Aust. J. Chem.*, **2016**, *69*(3), 279–290.
34. Adeyemi, J. O.; Onwudiwe, D. C. Organotin(IV) Dithiocarbamate Complexes: Chemistry and Biological Activity. *Molecules.*, **2018**, *23*(10), 2571.
35. Otera, J. ¹¹⁹Sn Chemical Shifts in Five- and Six-Coordinate Organotin Chelates. *J. Organomet. Chem.*, **1981**, *221*(1), 57–61.
36. Jung, O. S.; Hwa Jeong, J.; Soo Sohn, Y. Preparation, Properties and Structures of Estertin(IV) Sulphides. *Polyhedron.*, **1989**, *8*(21), 2557–2563.
37. Muthalib, A. F. A.; Baba, I.; Farina, Y.; Samsudin, M. W. Synthesis and Characterization of Diphenyltin(IV) Dithiocarbamate Compounds (Sintesis Dan Pencirian Sebastian Difenilstanum(IV) Ditiokarbamat). *Malaysian J. Anal. Sci.*, **2011**, *15*(1), 106-112.

38. Abd Aziz, N. A.; Awang, N.; Chan, K. M.; Kamaludin, N. F.; Mohamad Anuar, N. N.; Jamaludin, N. A. N.; Tan, Y. S.; Tiekink, E. R. T. Crystal Structure of Bis[Benzyl(Methyl)Carbamodithioato-k 2S,S]-Di-n-Butyltin(IV), $C_{26}H_{38}N_2S_4Sn$. *Zeitschrift fur Kristallographie- New Crystal Structures.*, **2023**, *238*(1), 15–18.
39. Pellerito, C.; Nagy, L.; Pellerito, L.; Szorcsik, A. Biological Activity Studies on Organotin(IV) N+ Complexes and Parent Compounds. *J. Organomet. Chem.*, **2006**, *691*(8), 1733-1747.
40. Adeyemi, J. O.; Onwudiwe, D. C. Antimicrobial and Cytotoxicity Studies of Some Organotin(IV) N-Ethyl-N-Phenyl Dithiocarbamate Complexes. *Pol. J. Environ. Stud.*, **2020**, *29*(4), 2525–2532.
41. Koch, B.; Basu Baul, T. S.; Chatterjee, A. P53-Dependent Antiproliferative and Antitumor Effect of Novel Alkyl Series of Diorganotin(IV) Compounds. *Invest. New Drugs.*, **2009**, *27*(4), 319–326.
42. Ray, D.; das Sarma, K.; Antony, A. Differential Effects of Tri-n-Butylstannyl Benzoates on Induction of Apoptosis in K562 and MCF-7 Cells. *IUBMB Life.*, **2000**, *49*(6), 519–525.
43. Wada, O.; Manabe, S.; Iwai, H.; Arakawa, Y. Recent Progress in the Study of Analytical Methods, Toxicity, Metabolism and Health Effects of Organotin Compounds. *Sangyo Igaku.*, **1982**, *24*(1), 24-54.